Lantheus (NASDAQ:LNTH) Stock Price Up 7.2% – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares traded up 7.2% during trading on Monday . The stock traded as high as $78.00 and last traded at $77.80. 1,372,245 shares were traded during trading, an increase of 51% from the average session volume of 910,950 shares. The stock had previously closed at $72.56.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Truist Financial lifted their price objective on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research note on Friday, February 27th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Mizuho increased their price objective on shares of Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Stock Performance

The firm has a 50 day moving average of $69.11 and a two-hundred day moving average of $60.98. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. The stock has a market cap of $5.17 billion, a PE ratio of 23.79 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same period in the prior year, the firm posted $1.59 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Institutional Trading of Lantheus

A number of large investors have recently made changes to their positions in the company. Hantz Financial Services Inc. grew its stake in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus in the second quarter valued at approximately $26,000. First Horizon Corp purchased a new position in shares of Lantheus during the third quarter worth approximately $26,000. Smartleaf Asset Management LLC grew its position in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Finally, Parallel Advisors LLC increased its holdings in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 298 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.